Concentra Group Holdings Parent (CON) Q2 2024 earnings summary

Executive summary

• Revenue for Q2 2024 increased 2.3% year-over-year to $477.9 million, driven by higher revenue per visit despite a slight decline in total patient visits.

• Adjusted EBITDA rose 1.2% to $101.6 million, with margin at 21.3%; net income was $53.1 million, down 1.8%.

• Completed IPO in July 2024, raising up to $528.8 million in gross proceeds and listing on NYSE under "CON."

• Expanded footprint to 547 occupational health centers and 154 onsite clinics as of June 30, 2024.

• Board expanded with three independent directors, enhancing healthcare and operational expertise.

Financial highlights

• Q2 2024 revenue: $477.9 million (up 2.3% year-over-year); six-month revenue: $945.5 million (up 2.4%).

• Adjusted EBITDA for Q2 2024: $101.6 million (21.3% margin); six-month Adjusted EBITDA: $197.7 million (20.9% margin).

• Net income was $53.1 million; EPS was $0.50, with adjusted EPS at $0.49.

• Revenue per visit increased 3.9% year-over-year in Q2 2024 to $139.81.

• Cost of services was 71% of revenue, up from 70.6% year-over-year.

Outlook and guidance

• Rate environment expected to remain consistent for the rest of 2024, with long-term rate trends in line with historical patterns.

• Anticipates growth in Florida due to a new workers' compensation reimbursement law effective January 2025.

• Long-term targets include mid- to high single-digit revenue growth, 20%+ Adjusted EBITDA margin, and free cash flow conversion above 80%.

• Net leverage targeted to decrease from 3.9x at IPO launch to below 3.0x within 24 months.

• Management expects continued positive cash flow and sufficient liquidity for at least the next 12 months.